All In Biotech

Drug Trial Radar · NCT04795531

A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3)

A 26-week Double Blinded, Multiregional, Trial Comparing the Effect and Safety of Once Weekly Insulin Icodec and Once Daily Insulin Degludec 100 Units/mL, Both in Combination With Non-insulin Anti-diabetic Drugs, in Insulin naïve Subjects With Type 2 Diabetes.

Last checked: Nov 20, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 588 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

588

Actual

Start

Mar 24, 2021

Primary completion

Jun 23, 2022

Study completion Jun 23, 2022

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Mar 12, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study compares insulin icodec (a new insulin taken once a week) to insulin degludec (an insulin taken once daily which is already available on the market) in people with type 2 diabetes. The study will look at how well insulin icodec taken weekly controls blood sugar compared to insulin degludec taken daily. Participants will get their study medicine in an injection pen. Participants will get a pen for weekly injection and one for daily injection. One will be icodec or degludec and the other will be dummy medicine. The treatment participants get is decided by chance. Participants and the study staff will not know which active medicine they get. The insulin is injected with a needle in a skin fold in the thigh. The study could last for about 8 months. Participants will have 13 clinic visits and 17 phone calls with the study doctor. At 8 clinic visits participants will have blood samples taken. At 4 clinic visits participants cannot eat or drink (except for water) for 8 hours before the visit. Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • Insulin icodecDrug

    You will get a pen for weekly injection and one for daily injection. One will be icodec 700 units/mL and the other will be placebo. Subcutaneously (under the skin) injections

  • Placebo insulin icodecDrug

    You will get a pen for weekly injection and one for daily injection. One will be insulin degludec 100 units/mL and the other will be placebo. Subcutaneously (under the skin) injections

  • Insulin degludecDrug

    You will get a pen for weekly injection and one for daily injection. One will be degludec 100 units/mL and the other will be placebo. Subcutaneously (under the skin) injections

  • Placebo insulin degludecDrug

    You will get a pen for weekly injection and one for daily injection. One will be icodec 700 units/mL and the other will be placebo. Subcutaneously (under the skin) injections

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Glycated Haemoglobin (HbA1c)Time frame: Baseline (Week 0), Week 26

Locations

190 sites in 12 countries. Site status is shown where the registry gives one.

  • Univ of Alabama Birmingham

    Birmingham, Alabama

  • Lakeview Clinical Research, LLC

    Guntersville, Alabama

  • Lynn Institute of the Ozarks

    Little Rock, Arkansas

  • Anaheim Clinical Trials, LLC

    Anaheim, California

  • Advanced Clinical Research/Rancho Paseo Medical Group

    Banning, California

  • American Clinical Trials

    Buena Park, California

  • Med Center Medical Clinic

    Carmichael, California

  • Headlands Research California, LLC

    Escondido, California

  • Valley Research

    Fresno, California

  • Scripps Whittier Diabetes Inst

    La Jolla, California

  • First Valley Medical Group

    Lancaster, California

  • Clinical Trials Research_Sacramento

    Lincoln, California

  • Torrance Clin Res Inst, Inc.

    Lomita, California

  • Providence Clinical Research

    North Hollywood, California

  • Valley Clinical Trials, Inc.

    Northridge, California

  • Desert Oasis Hlthcr Med Group

    Palm Springs, California

  • NorCal Endocrinology and Internal Medicine

    San Ramon, California

  • Diabetes Research Center

    Tustin, California

  • Coastal Metabolic Research Center

    Ventura, California

  • Denver Endocrinology Diabetes and Thyroid Center

    Englewood, Colorado

  • Chase Medical Research LLC

    Waterbury, Connecticut

  • Revival Research

    Doral, Florida

  • Est Cst Inst for Rsrch,Jksnvil

    Jacksonville, Florida

  • Jacksonville Ctr For Clin Res

    Jacksonville, Florida

  • University Of Miami

    Miami, Florida

  • Suncoast Clinical Research, Inc.

    New Port Richey, Florida

  • Florida Institute for Clinical research

    Orlando, Florida

  • Palm Harbor Medical Associates

    Palm Harbor, Florida

  • Suncoast Clinical Research, Inc.

    Palm Harbor, Florida

  • Metabolic Research Institute Inc

    West Palm Beach, Florida

  • Clinical Research of Cent FL

    Winter Haven, Florida

  • Physicians Research Assoc. LLC

    Lawrenceville, Georgia

  • RNA America Health Sciences

    Sugar Hill, Georgia

  • East West Med Res Inst

    Honolulu, Hawaii

  • Elite Clinical Trials

    Blackfoot, Idaho

  • Cedar-Crosse Research Center

    Chicago, Illinois

  • Iowa Diab & Endo Res Center

    West Des Moines, Iowa

  • Cotton-Oneill Diabetes and End

    Topeka, Kansas

  • St Elizabeth Physicians Heart

    Covington, Kentucky

  • Four Rivers Clinical Research Inc

    Paducah, Kentucky

Showing 40 of 190 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.